Over the past decade, the non-invasive prenatal test (NIPT) has increasingly been used as a method for prenatal screening for trisomy 21 (T21) and other aneuploidies, complementing the traditional approach of first trimester screening (FTS). FTS comprises ultrasound of the nuchal thickness and blood test to measure the levels of maternal serum free-β-human chorionic gonadotropin and pregnancy-associated plasma protein-A (PAPP-A).
This article is available only as a PDF. Please click on “Download PDF” to view the full article.
